NL-OMON33866已完成2 期
PHASE II STUDY OF LUTETIUM-177 LABELED CHIMERIC MONOCLONAL ANTIBODY cG250 (177Lu-DOTA-cG250) IN PATIENTS WITH ADVANCED RENAL CANCER - Phase 2 radioimmunotherapy in M+ RCC
niversitair Medisch Centrum Sint Radboud0 个研究点目标入组 9 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 9
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •Patients with proven advanced and progressive renal cell carcinoma of the clear cell type
- •Performance status: Karnofsky > 70 %
- •Adequate bone marrow function
- •Age over 18 years
排除标准
- •Known metastases to the brain
- •Metastatic disease limited to the bone
- •Pre-exposure to murine/chimeric antibody
- •Chemotherapy, external beam radiation, immunotherapy or angiogenesis inhibitors within 4 weeks prior to study.
- •Life expectancy shorter than 6 months.
研究者
相似试验
进行中（未招募）
不适用
PHASE II STUDY OF LUTETIUM-177 LABELED CHIMERIC MONOCLONAL ANTIBODY cG250 (177Lu-DOTA-cG250) IN PATIENTS WITH ADVANCED RENAL CANCER - Phase II LutetiumEUCTR2008-004548-35-NLRadboud university nijmegen medical centre
进行中（未招募）
1 期
Trial investigating the activity of 177 Lutetium dotatate in children with cancer in their nervous systemEUCTR2012-000510-10-GBniversity of Birmingham24
尚未招募
2 期
A study to evaluate the effectiveness of 177-Lu-DOTA Rituximab drug in adult patients diagnosed with the recurrence of low-grade B-cell lymphomas (a type of blood cancer).CTRI/2021/02/031578Tata Research Administrative Council TRAC
进行中（未招募）
1 期
Treatment of lymphoma with targeted internal radiation therapy(Betalutin)EUCTR2011-000033-36-HUordic Nanovector ASA200
进行中（未招募）
1 期
Treatment of lymphoma with targeted internal radiation therapy(Betalutin)EUCTR2011-000033-36-NLordic Nanovector ASA130